Cargando…

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review

Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress. Circulating tumor DNA (ctDNA) is a DNA fragment actively secreted by tumor cells or released...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Lemei, Xu, Ran, Yang, Leilei, Shi, Wei, Zhang, Yuan, Liu, Juan, Li, Xi, Zhou, Jun, Bing, Pingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448395/ https://www.ncbi.nlm.nih.gov/pubmed/37636270 http://dx.doi.org/10.3389/fgene.2023.1172108

Ejemplares similares

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Peng, Yan, et al.
Publicado: (2021)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy
por: Lutfi, Areeb, et al.
Publicado: (2023)

Fragment Enrichment of Circulating Tumor DNA With Low-Frequency Mutations
por: Liu, Xiaojun, et al.
Publicado: (2020)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)
por: Chen, Huijuan, et al.
Publicado: (2023)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
por: Fang, Xiaoxu, et al.
Publicado: (2022)

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
por: Semenkovich, Nicholas P, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
por: Kurtz, David M., et al.
Publicado: (2021)

Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis
por: Zhong, Ran, et al.
Publicado: (2023)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Advances in early detection methods for solid tumors
por: Jiang, Bowen, et al.
Publicado: (2023)

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
por: Kasi, Pashtoon M., et al.
Publicado: (2022)

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
por: Jiang, Jiahong, et al.
Publicado: (2020)

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
por: Gong, Jun, et al.
Publicado: (2021)

Editorial: Genetic and proteomic biomarkers in solid tumor detection and treatment
por: Li, Jitian, et al.
Publicado: (2023)

Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients
por: Sharbatoghli, Mina, et al.
Publicado: (2022)

Minimal residual disease and circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
por: Jia, Ning, et al.
Publicado: (2019)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
por: Reece, Mifanwy, et al.
Publicado: (2019)

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients
por: Coombes, RC, et al.
Publicado: (2005)

Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
por: Wang, Siwei, et al.
Publicado: (2022)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023)

Editorial: Recent advances in genetic and proteomic biomarkers involved in the early detection of solid tumors
por: Li, Jitian, et al.
Publicado: (2023)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article
por: Dong, Qiantong, et al.
Publicado: (2023)

Non-Coding RNAs in Pediatric Solid Tumors
por: Smith, Christopher M., et al.
Publicado: (2019)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Using single-cell sequencing technology to detect circulating tumor cells in solid tumors
por: Xu, Jiasheng, et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing
por: Anisetti, Bhrugun, et al.
Publicado: (2023)

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

Correction to: Using single-cell sequencing technology to detect circulating tumor cells in solid tumors
por: Xu, Jiasheng, et al.
Publicado: (2022)

Integrated analysis of circulating tumour cells and circulating tumour DNA to detect minimal residual disease in hepatocellular carcinoma
por: Zhao, Lina, et al.
Publicado: (2022)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7gm6j1uo4a6k2ng3q6cdtrlgk8